Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

Twinhale In silico trials for pulmonary drug delivery with breakthrough digital twins of the lungs

Coordinator
Ebenbuild GmbH, Germany
Runs
1 October 2025 to 30 September 2027
Status
Running
EU funding
€2.3m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101247575

What the project is doing

In the project's own words, from its summary on CORDIS.

Due to the limitedness of current technologies, the respiratory system has historically been a sort of black box in many aspects of R&D and clinical practice. At Ebenbuild we want to open this black box by building the first accurate, patient-specific simulation models of the lungs, the so-called digital twins of the lungs. In addition to patient data, these are based on first-of-a-kind predictive, physiologically accurate computational models of the respiratory system.

By opening the black box for the very first time, our technology holds the potential to become the definitive source of health intelligence for respiratory diseases across a variety of use cases in healthcare and life sciences, from preclinical R&D to point-of-care. This will make Ebenbuild a deep-tech vanguard with a diversified spectrum of scalable products, each with a significant patient benefit and a global revenue potential and with our technological platform at their core.

With EIC support we aim at expanding and validating the potential of our technology for provision of Twinhale tool to Biotech, MedTech and Pharma companies. Twinhale supports in-silico trials for pulmonary drug delivery and enables faster development of better inhalable treatments. Achieving this milestone will not only unlock an intriguing business opportunity, but will also be the starting point to further develop and eventually position our platform products along the entire spectrum of the medical value chain, from the inception of novel therapies to their application at the point-of-care.

Topics

Who is involved

OrganisationCityCountryRole
Ebenbuild GmbHMunchenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI